BETs abet Tam-R in ER-positive breast cancer
Epigenetic modifications such as histone acetylation play a central role in the transcriptional regulation of many oncogenic drivers.Accumulating evidence suggests that pharmacological modulation of certain key epigenetic reader proteins such as BRD2/3/4 may serve as an attractive strategy for treatment of many cancers,including tamoxifen-resistant breast cancer.Estrogen receptor (ER)-positive breast cancer represents approximately 70% of all breast cancers and the selective ER modulator (SERM),tamoxifen,remains the mainstay of treatment in pre-menopausal women ”1”.Although several studies have established the role oftamoxifen in significantly reducing disease recurrence and death from breast cancer,acquired resistance to tamoxifen remains a major clinical challenge ”1”.Several signaling cascades have been implicated in the development of endocrine therapy resistance,including HER2,MAP kinase,PI3K-mTOR,IGF-IR and FGFR pathways ”2”.However,the role ofepigenetic alterations of ER in tamoxifen resistance is poorly understood.
24
2014-09-10(万方平台首次上网日期,不代表论文的发表时间)
899-900